Precipio, Inc. competitors & alternatives

Scopio LabsMedical DevicesIsrael

68% matchPrivate

Similar medical devices company

Scopio Labs provides digital hematology imaging platforms and AI-powered analysis applications for peripheral blood smears and bone marrow aspirates. The company's technology enables clinical laboratories to fully digitize morphology workflows, view high-resolution 100x scans remotely, and collaborate across networks.

CellaVision0MR5 · Medical DevicesSweden

67% matchPublic

Similar medical devices company

CellaVision provides digital hematology microscopy solutions, including hardware analyzers, instruments, reagents, and specialized software applications. The company automates and streamlines workflows for human and veterinary laboratories of all sizes to analyze blood and body fluid samples.

Similar medical devices company

Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.

Beckman Coulter DiagnosticsMedical Devices, Diagnostics, Life SciencesIsrael

64% match

Medical Devices, Diagnostics, Life Sciences

Beckman Coulter Diagnostics provides clinical diagnostic products, laboratory automation systems, and testing solutions across disciplines such as chemistry, immunoassay, hematology, and microbiology. The company serves healthcare providers and laboratories by delivering accurate and timely diagnostic insights to inform clinical decisions and improve patient care.

OraSure Technologies, Inc.OSUR · Medical DevicesBethlehem, United States

63% matchPublic

Similar medical devices company

OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.

Medical - Devices

Applied BioCode Corporation specializes in the complete lifecycle—from design and development to manufacturing and commercialization—of multiplex diagnostic testing solutions tailored for the In-Vitro Diagnostics (IVD) market. Among its key offerings are two sophisticated systems: the BioCode MDx 3000, an automated molecular diagnostics platform that streamlines PCR amplification, hybridization, and detection steps; and the BioCode 2500 analyzer, specifically engineered to read barcoded magnetic beads (BMBs) and display their unique identification along with fluorescence intensity. The company also boasts an extensive portfolio of diagnostic assays, including the BioCode SARS-CoV-2 Assay, a high-throughput, automated nucleic acid multiplex test for detecting SARS-CoV-2 genetic material in nasopharyngeal swabs. Other panels comprise BioCode Respiratory Pathogen Panels, capable of simultaneously identifying and differentiating seventeen distinct respiratory pathogens in nasopharyngeal samples, and BioCode gastrointestinal (GI) pathogen panels, which target prevalent GI pathogens such as viruses, bacteria, and parasites responsible for infectious diarrheal diseases. An expanding pipeline of MDx assays for various molecular tests is also under development. Beyond these, Applied BioCode provides specialized reagents like analyte-specific reagents for fungal pathogens, and multiplex kits for human cytokines and chemokines, vital for biomarker identification. For research flexibility, they offer premixed and customizable multiplex kits for mouse models, alongside similar cytokine/chemokine multiplex kits for rat, monkey, canine, and non-human primate studies. Rounding out its comprehensive services, the company supplies its proprietary BMBs, calibration beads, and coupling kits for a wide array of bioassay applications. They also offer ELISA (Enzyme-Linked Immunosorbent Assay), a method for the precise quantification of drug, protein, or antibody levels in biological samples such as cell lysates or serum, in addition to providing full-spectrum assay development services. Applied BioCode Corporation is headquartered in Santa Fe Springs, California.

Biofire GroupMedical Devices

62% match

Similar medical devices company

Biofire Group develops syndromic infectious disease diagnostics systems and multiplex PCR testing panels. The company serves clinical laboratories and healthcare providers by delivering rapid detection results for pathogens such as viruses, bacteria, and resistance genes.

EKF DIAGNOSTICS HOLDINGS PLCEKF · Medical DevicesCardiff, United Kingdom

62% matchPublic

Similar medical devices company

EKF Diagnostics Holdings plc, a company founded in 1990 and based in Cardiff, United Kingdom, operates as an international supplier of diagnostic solutions. The firm excels in the development, manufacturing, and distribution of a wide array of diagnostic instruments, chemical reagents, and associated products. Its extensive market reach spans across Europe, the Middle East, the Americas, Asia, Africa, and beyond. The company's product lineup addresses various critical diagnostic needs. This includes a range of hemoglobin analysis devices, such as the handheld DiaSpect Tm and the quantitative Hemo Control. EKF also provides advanced glucose and lactate analyzers like the Biosen C-Line series, alongside point-of-care solutions for diabetes management, exemplified by the Quo-Lab A1c and Quo-Test A1c. Beyond these, their offerings extend to specialized diagnostic tools: the Creamatocrit Plus for assessing lipid concentration in mothers' milk, QuPID and True20 pregnancy tests, and the STAT-Site M Beta-hydroxybutyrate analyzer. EKF further supplies a comprehensive suite of clinical chemical analyzers and reagents, designed for monitoring conditions such as ketosis, glycated albumin, glycated serum protein, and utilizing markers like Procalcitonin for bacterial infections and sepsis. Additional provisions include immunoassay kits, general chemistry analyzers like the Altair 240, micro centrifuges, the Uri-Trak 120 urine analyzer, and dedicated kits and services for COVID-19. The company also offers its manufacturing capabilities as contract solutions to third-party businesses and delivers professional laboratory services.

Medical Devices (In Vitro Diagnostics)

Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical diagnostic products, from their initial research and development to manufacturing and market distribution. Their diverse offerings encompass a range of reagents for immunoassay, biochemistry, microbiology, and in-vitro diagnostics (IVD). Additionally, they provide advanced automated and semi-automated instrumentation, alongside comprehensive medical laboratory solutions. Notable immunoassay products include the AutoLumo A2000 Plus automatic chemiluminescence immunoassay analyzer, automated microplate chemiluminescent enzyme immunoassays, LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Within their microbiology division, they offer automated blood culture systems, blood culture bottles, AUTOMIC strips, and mycoplasma IES. Founded in 1998, the company originally operated as Lifeclone Diagnostics Co., Ltd. before adopting its current name, Autobio Diagnostics Co., Ltd., in 2003. Headquartered in Zhengzhou, China, it functions as a subsidiary of Zhengzhou Auto Industrial Co., Ltd.

Similar medical devices company

CelLBxHealth plc, formerly known as ANGLE plc until its name change in October 2025, is a medical diagnostics enterprise established in 1994 and headquartered in Guildford, United Kingdom. The company is dedicated to developing advanced cancer diagnostic products, serving markets across the United Kingdom, Europe, North America, and other international regions. Its core offerings include the Parsortix PC1 and PR1 systems, which are innovative medical devices engineered to capture and retrieve intact circulating tumor cells (CTCs) from patient blood. Specifically, the PC1 system is designed for metastatic breast cancer samples, facilitating subsequent user-validated downstream analysis. CelLBxHealth also provides the Portrait+ CTC Staining kit, a laboratory solution for the identification, characterization, and enumeration of epithelial and mesenchymal CTCs with high analytical sensitivity and specificity, alongside the CellKeep Slide technology for CTC harvesting. In addition to these products, the company delivers a suite of laboratory services, including CTC enrichment and liquid biopsy analysis. Specialized assays are also available, such as Portrait Flex for immunofluorescence-based identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition, Portrait PD-L1 for CTC evaluation, and bespoke custom CTC assays. Furthermore, CelLBxHealth plc has forged strategic alliances, including a partnership with BioView Ltd to co-develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and an agreement with NuProbe USA, Inc. for the application of its pan-cancer next-generation sequencing (NGS) panel.

Similar medical devices company

QuidelOrtho Corporation is dedicated to the creation and manufacturing of diagnostic testing technologies that address the full range of healthcare testing demands. The company operates through distinct business units: Laboratories, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics. The Laboratories segment provides instruments and assays for clinical chemistry, which measure specific chemical markers in bodily fluids to aid in health evaluation and patient management. It also offers immunoassay instruments and tests designed to detect proteins acting as antigens (indicating disease spread), antibodies (reflecting immune response), or markers of organ health and function. Furthermore, this unit develops testing solutions for monitoring disease progression across various therapeutic fields, along with specialized diagnostic tools. The Transfusion Medicine segment supplies immunohematology instruments and tests vital for blood typing, ensuring compatibility between patients and donors during transfusions, as well as donor screening instruments and tests for detecting infectious diseases in blood and plasma. The Point-of-Care business unit focuses on delivering rapid diagnostic tests suitable for diverse immediate care settings. Finally, the Molecular Diagnostics unit offers polymerase chain reaction (PCR) thermocyclers, alongside analyzers and amplification systems. QuidelOrtho distributes its products directly to end-users via its dedicated sales team and through a network of distributors. These offerings are employed professionally in a wide array of environments, including physician practices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening facilities, blood banks, and donor centers. The company's products are also available for individual, non-professional, and over-the-counter use. With operations spanning North America, Europe, the Middle East, Africa, China, and other global regions, QuidelOrtho Corporation was founded in 1979 and maintains its headquarters in San Diego, California.

MedMira Inc.Medical DevicesHalifax, Canada

65% match

Similar medical devices company

MedMira Inc. is a biotechnology company focused on the research, development, manufacturing, and global commercialization of rapid diagnostic solutions and related technology platforms. Its operations span North America, Europe, the Asia Pacific region, and other international markets. MedMira offers a diverse portfolio of rapid diagnostic tests and technology platforms. Its diagnostic solutions include Reveal HIV, which identifies HIV-1 and HIV-2 antibodies in various blood samples; Reveal TP, a rapid test for syphilis antibodies (Treponema pallidum); and Reveal HP, designed to detect Helicobacter pylori antibodies. The company also provides Multiplo, a line of multiplex tests for combined screening of conditions such as HIV-1/2, Hepatitis B and C, and syphilis, as well as the Miriad triple product for initial HIV and hepatitis screening. In the realm of respiratory and viral diagnostics, MedMira developed VYRA CoV2 for SARS-CoV-2 nucleocapsid antigen detection, VYRA CoV2Flu for simultaneous antigen testing of SARS-CoV-2, Influenza A, and Influenza B, and REVEALCOVID-19, an antibody test for COVID-19. Beyond diagnostic kits, MedMira provides the Miriad RVF toolkit, a platform that facilitates the development and market entry of rapid diagnostics. MedMira distributes its offerings through a wide network of medical distributors and strategic partners. Its customer base is broad, serving various segments of the healthcare industry, including clinical laboratories, hospitals, point-of-care clinics, government agencies, humanitarian aid groups, and public health bodies. The company was established in 1993, is headquartered in Halifax, Canada, and operates as a subsidiary of MedMira Holding AG.